Exhibit 107
Calculation of Filing Fee Table
Form S-8
AcelRx Pharmaceuticals, Inc.
Table 1: Newly Registered Securities
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
Equity | Common Stock, $0.001 par value per share, 2020 Equity Incentive Plan | Other | 1,500,000 | $0.48(2) | $720,000(2) | 0.00014760 | $106.28 |
Total Offering Amounts | $720,000 | $106.28 | |||||
Total Fee Offsets | — | ||||||
Net Fee Due | $106.28 |
(1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock that become issuable under the AcelRx Pharmaceuticals, Inc. Amended and Restated 2020 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of AcelRx Pharmaceuticals, Inc.’s (the “Registrant”) common stock, as applicable. |
(2) | Estimated pursuant to Rules 457(c) and 457(h) under the Securities Act, solely for the purposes of calculating the registration fee and based on the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on November 15, 2023, rounded up to the nearest cent, which date is within five business days prior to the filing of this Registration Statement. |